{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T07:33:46Z","timestamp":1740123226083,"version":"3.37.3"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2017,1,21]],"date-time":"2017-01-21T00:00:00Z","timestamp":1484956800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Ophthalmol"],"DOI":"10.1007\/s10792-017-0447-0","type":"journal-article","created":{"date-parts":[[2017,1,20]],"date-time":"2017-01-20T20:11:48Z","timestamp":1484943108000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Intravitreal anti-VEGF treatment for subretinal neovascularisation secondary to type 2 idiopathic juxtafoveolar telangiectasia"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9748-6171","authenticated-orcid":false,"given":"Teresa","family":"Barth","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Florian","family":"Zeman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Horst","family":"Helbig","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria-Andreea","family":"Gamulescu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,1,21]]},"reference":[{"key":"447_CR1","first-page":"136","volume":"100","author":"JD Gass","year":"1993","unstructured":"Gass JD, Blodi BA (1993) Idiopathic juxtafoveolar retinal telangiectasis. Update of classification and follow-up study. Ophthalmology 100:136\u2013146","journal-title":"Ophthalmology"},{"issue":"3","key":"447_CR2","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1001\/archopht.120.3.320","volume":"120","author":"NE Engelbrecht","year":"2002","unstructured":"Engelbrecht NE, Aaberg TM, Sung J, Lewis ML (2002) Neovascular membranes associated with idiopathic juxtafoveolar telangiectasis. Arch Ophthalmol 120(3):320\u2013324","journal-title":"Arch Ophthalmol"},{"key":"447_CR3","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.preteyeres.2012.11.002","volume":"34","author":"P Charbel Issa","year":"2013","unstructured":"Charbel Issa P, Gillies MC, Chew EY et al (2013) Macular telangiectasia type 2. Prog Retin Eye Res 34:49\u201377","journal-title":"Prog Retin Eye Res"},{"key":"447_CR4","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1007\/s00417-013-2491-4","volume":"252","author":"J Chhablani","year":"2014","unstructured":"Chhablani J, Mithal K, Rao H, Narayanan R (2014) Diagnosis of subretinal neovascularization associated with idiopathic juxtafoveal retinal telangiectasia: fluorescein angiography versus spectra-domain optical coherence tomography. Graefes Arch Clin Exp Ophthalmol 252:549\u2013553","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"11","key":"447_CR5","doi-asserted-by":"crossref","first-page":"2150","DOI":"10.1097\/IAE.0000000000001035","volume":"36","author":"O Toygar","year":"2016","unstructured":"Toygar O, Guess MG, Youssef DS, Miller DM (2016) Long-term outcomes of intravitreal bevacizumab therapy for subretinal neovascularization secondary to idiopathic macular telangiectasia type 2. Retina 36(11):2150\u20132157","journal-title":"Retina"},{"issue":"12","key":"447_CR6","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1007\/s00417-007-0567-8","volume":"245","author":"S Mandal","year":"2007","unstructured":"Mandal S, Venkatesh P, Abbas Z, Vohra R, Garg S (2007) Intravitreal bevacizumab (Avastin) for subretinal neovascularization secondary to type 2A idiopathic juxtafoveal telangiectasia. Graefes Arch Clin Exp Ophthalmol 245(12):1825\u20131829","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"1","key":"447_CR7","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/S0002-9394(01)01205-3","volume":"133","author":"MJ Potter","year":"2002","unstructured":"Potter MJ, Szabo SM, Chan EY, Morris AHC (2002) Photodynamic therapy of a subretinal neovascular membrane in type 2A idiopathic juxtafoveolar retinal telangiectasis. Am J Ophthalmol 133(1):149\u2013151","journal-title":"Am J Ophthalmol"},{"issue":"5","key":"447_CR8","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1016\/j.ajo.2004.05.073","volume":"138","author":"LM Smithen","year":"2004","unstructured":"Smithen LM, Spaide RF (2004) Photodynamic therapy and intravitreal triamcinolone for a subretinal neovascularization in bilateral idiopathic juxtafoveal telangiectasis. Am J Ophthalmol 138(5):884\u2013885","journal-title":"Am J Ophthalmol"},{"key":"447_CR9","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1016\/S0161-6420(97)30019-0","volume":"10","author":"DW Park","year":"1997","unstructured":"Park DW, Schatz H, McDonald HR, Johnson RN (1997) Grid laser photocoagulation for macular edema in bilateral juxtafoveal telangiectasis. Ophthalmology 10:1838\u20131846","journal-title":"Ophthalmology"},{"issue":"1","key":"447_CR10","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.ajo.2004.01.047","volume":"138","author":"D Shukla","year":"2004","unstructured":"Shukla D, Singh J, Kolluru CM, Kim R, Namperumalsamy P (2004) Transpupillary thermotherapy for subfoveal neovascularization secondary to group 2A idiopathic juxtafoveolar telangiectasis. Am J Ophthalmol 138(1):147\u2013149","journal-title":"Am J Ophthalmol"},{"key":"447_CR11","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1016\/j.ajo.2003.11.076","volume":"137","author":"AS Berger","year":"2004","unstructured":"Berger AS, McCuen BW II, Brown GC, Brownlow RL (2004) Surgical Removal of subfoveal neovascular membrane in type 2A idiopathic juxtafoveolar retinal telangiectasis. Am J Ophthalmol 137:812\u2013819","journal-title":"Am J Ophthalmol"},{"key":"447_CR12","doi-asserted-by":"crossref","first-page":"e00776","DOI":"10.1136\/bmjopen-2015-007746","volume":"5","author":"A Stuart","year":"2015","unstructured":"Stuart A, Ford JA, Duckworth S, Jones C, Pereira A (2015) Anti-VEGF therapies in the treatment of choroidal neovascularisation secondary to on-age-related macular degeneration: a systematic review. BMJ Open 5:e00776","journal-title":"BMJ Open"},{"issue":"7","key":"447_CR13","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1007\/s00417-006-0468-2","volume":"245","author":"R Jorge","year":"2007","unstructured":"Jorge R, Costa RA, Calucci D, Scott IU (2007) Intravitreal bevacizumab (Avastin) associated with the regression of subretinal neovascularization in idiopathic juxtafoveolar retinal telangiectasis. Graefes Arch Clin Exp Ophthalmol 245(7):1045\u20131048","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"447_CR14","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1007\/s00417-009-1117-3","volume":"247","author":"L Konstantinidis","year":"2009","unstructured":"Konstantinidis L, Mantel I, Zografos L, Ambresin A (2009) Intravitreal ranibizumab as primary treatment for neovascular membrane associated with idiopathic juxtafoveal retinal telangiectasia. Graefes Arch Clin Exp Ophthalmol 247:1567\u20131569","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"8","key":"447_CR15","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1111\/j.1755-3768.2009.01598.x","volume":"87","author":"N Mavrakanas","year":"2009","unstructured":"Mavrakanas N, Mendrinos E, Pournaras CJ, Salzmann J (2009) Intravitreal ranibizumab and bevacizumab for bilateral subretinal neovascularization secondary to idiopathic juxtafoveal telangiectasia type 2A. Acta Ophthalmol 87(8):930\u2013932","journal-title":"Acta Ophthalmol"},{"issue":"10","key":"447_CR16","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1097\/IAE.0b013e3182625c1d","volume":"32","author":"R Narayanan","year":"2012","unstructured":"Narayanan R, Chhablani J, Sinha M et al (2012) Efficacy of anti-vascular endothelial growth factor therapy in subretinal neovascularization secondary to macular telangiectasia type 2. Retina 32(10):2001\u20132005","journal-title":"Retina"},{"issue":"9","key":"447_CR17","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1097\/IAE.0b013e31820d3feb","volume":"31","author":"AB Roller","year":"2011","unstructured":"Roller AB, Folk JC, Patel NM et al (2011) Intravitreal bevacizumab for treatment of proliferative and nonproliferative type 2 idiopathic macular telangiectasia. Retina 31(9):1848\u20131855","journal-title":"Retina"},{"issue":"4","key":"447_CR18","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1007\/s00417-007-0732-0","volume":"246","author":"P Rishi","year":"2008","unstructured":"Rishi P, Shroff D, Rishi E (2008) Combined photodynamic therapy and intravitreal ranibizumab as primary treatment for subretinal neovascular membrane (SRNVM) associated with type 2 idiopathic macular telangiectasia. Graefes Arch Clin Exp Ophthalmol 246(4):619\u2013621","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"5","key":"447_CR19","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1016\/j.ajo.2010.11.019","volume":"151","author":"P Charbel Issa","year":"2011","unstructured":"Charbel Issa P, Finger RP, Kruse K, Baumuller S, Scholl HPN, Holz FG (2011) Monthly ranibizumab for nonproliferative macular telangiectasia type 2: a 12-month prospective study. Am J Ophthalmol 151(5):876\u2013886","journal-title":"Am J Ophthalmol"},{"issue":"10","key":"447_CR20","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1097\/IAE.0000000000000203","volume":"34","author":"DV Do","year":"2014","unstructured":"Do DV, Bressler SB, Cassard SD et al (2014) Ranibizumab for macular telangiectasia type 2 in the absence of subretinal neovascularization. Retina 34(10):2063\u20132071","journal-title":"Retina"},{"issue":"12","key":"447_CR21","doi-asserted-by":"crossref","first-page":"2619","DOI":"10.1097\/IAE.0000000000000715","volume":"35","author":"EH Kupitz","year":"2015","unstructured":"Kupitz EH, Heeren TFC, Holz FG, Charbel Issa P (2015) Poor long-term outcome of anti-vascular endothelial growth factor therapy in nonproliferative macular telangiectasia type 2. Retina 35(12):2619\u20132626","journal-title":"Retina"},{"issue":"1","key":"447_CR22","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1097\/IAE.0b013e31818ba9de","volume":"29","author":"JL Kovach","year":"2009","unstructured":"Kovach JL, Rosenfeld PJ (2009) Bevacizumab (avastin) therapy for idiopathic macular telangiectasia type II. Retina 29(1):27\u201332","journal-title":"Retina"},{"issue":"8","key":"447_CR23","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1007\/s00417-008-0795-6","volume":"246","author":"M-A Gamulescu","year":"2008","unstructured":"Gamulescu M-A, Walter A, Sachs H, Helbig H (2008) Bevacizumab in the treatment of idiopathic macular telangiectasia. Graefes Arch Clin Exp Ophthalmol 246(8):1189\u20131193","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"11","key":"447_CR24","doi-asserted-by":"crossref","first-page":"2513","DOI":"10.1007\/s00417-013-2346-z","volume":"251","author":"T Meyer-ter-Vehn","year":"2013","unstructured":"Meyer-ter-Vehn T, Herzog S, Schargus M, Gobel W, Guthoff R (2013) Long-term course in type 2 idiopathic macular telangiectasia. Graefes Arch Clin Exp Ophthalmol 251(11):2513\u20132520","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"4","key":"447_CR25","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1159\/000346130","volume":"49","author":"CE Veloso","year":"2013","unstructured":"Veloso CE, Vianna RN, Pelayes DE, Nehemy MB (2013) Intravitreal bevacizumab for type 2 idiopathic macular telangiectasia. Ophthalmic Res 49(4):205\u2013208","journal-title":"Ophthalmic Res"},{"key":"447_CR26","doi-asserted-by":"crossref","first-page":"2619","DOI":"10.1097\/IAE.0000000000000715","volume":"35","author":"EH Kupitz","year":"2015","unstructured":"Kupitz EH, Heeren TF, Holz FG, Charbel Issa P (2015) Poor long-term outcome of anti-vascular endothelial growth factor therapy in nonproliferative macular telangiectasia type 2. Retina 35:2619\u20132626","journal-title":"Retina"}],"container-title":["International Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10792-017-0447-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10792-017-0447-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10792-017-0447-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,17]],"date-time":"2019-09-17T16:46:54Z","timestamp":1568738814000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10792-017-0447-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1,21]]},"references-count":26,"alternative-id":["447"],"URL":"https:\/\/doi.org\/10.1007\/s10792-017-0447-0","relation":{},"ISSN":["0165-5701","1573-2630"],"issn-type":[{"type":"print","value":"0165-5701"},{"type":"electronic","value":"1573-2630"}],"subject":[],"published":{"date-parts":[[2017,1,21]]}}}